Osiris Provides Update Regarding NASDAQ Listing Matters


Osiris Therapeutics, Inc. today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market . As previously disclosed, the Company received notifications from NASDAQ indicating that, as a result of the Company not timely filing with the Securities and Exchange Commission its Annual Report on Form 10-K for the year ended December 31, 2015 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2016 and June 30, 2016, the Company failed to comply with the periodic filing requirements in NASDAQ Listing Rule 5250 .



from Biotech News